Jamieson, Michael J. http://orcid.org/0000-0001-8007-3733
Byon, Wonkyung http://orcid.org/0000-0003-0852-5920
Dettloff, Richard W. http://orcid.org/0000-0001-8627-7841
Crawford, Matthew http://orcid.org/0000-0003-3424-7741
Gargalovic, Peter S. http://orcid.org/0000-0002-6262-2839
Merali, Samira J. http://orcid.org/0000-0001-6659-3687
Onorato, Joelle http://orcid.org/0000-0002-8128-6885
Quintero, Andres J. http://orcid.org/0000-0002-0405-6445
Russ, Cristina http://orcid.org/0000-0001-7248-9712
Clinical trials referenced in this document:
Documents that mention this clinical trial
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
https://doi.org/10.1016/j.ahj.2013.05.016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
https://doi.org/10.1016/s0140-6736(16)00741-8
Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
https://doi.org/10.1016/j.ahj.2014.06.005
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
https://doi.org/10.1016/j.ahj.2009.07.035
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
https://doi.org/10.1136/openhrt-2020-001471
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
https://doi.org/10.1136/openhrt-2018-000908
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial
https://doi.org/10.1007/s11239-019-01823-y
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
https://doi.org/10.1136/heartjnl-2017-312272
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60986-6
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
https://doi.org/10.1016/j.ahj.2014.09.006
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
https://doi.org/10.1136/heartjnl-2018-313351
Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial
https://doi.org/10.1016/j.ahj.2013.05.025
Documents that mention this clinical trial
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
https://doi.org/10.1016/j.ahj.2009.08.026
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Documents that mention this clinical trial
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Documents that mention this clinical trial
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Documents that mention this clinical trial
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Documents that mention this clinical trial
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
https://doi.org/10.1016/s0140-6736(09)62125-5
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Documents that mention this clinical trial
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Article History
Accepted: 26 January 2022
First Online: 16 May 2022
Change Date: 4 June 2022
Change Type: Update
Change Details: A peer-reviewed video was retrospectively added to this publication.
Declarations
:
: The development of this manuscript was funded by Bristol Myers Squibb and Pfizer.
: MJJ, WB, RWD, AJQ, and CR are employees and shareholders of Pfizer. MC is an employee of Pfizer. PG, JO, and SJM are employees and shareholders of Bristol Myers Squibb.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See ExternalRef removed for more information.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MJ had the original concept for the article, and all authors agreed on its scope and methodology. The literature search logic and methodology were developed by AQ and MC, who also conducted the search. All articles in the search output were reviewed by RD, JO, and MJ. WB and SJM wrote the pharmacokinetics section; RD wrote the retrospective observational data section; AQ and MC wrote the literature search methodology section; MJ wrote all other sections. All authors critically reviewed the work in its entirety and approved the final manuscript.